TIDMFUM
Futura Medical PLC
26 January 2023
26 January 2023
Futura Medical plc
("Futura" or the "Company")
Pre-launch of MED3000 Eroxon(TM) ahead of H1 2023 launch
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, announces that its
partner, Cooper Consumer Health ("Cooper") has initiated pre-launch
activities ahead of the launch of MED3000 (Eroxon(TM)), Futura's
breakthrough, topical gel formulation for the treatment of erectile
dysfunction ("ED").
In May 2022, Futura announced an exclusive licensing agreement
with Cooper, a leading International independent self-care
organisation for the rights to commercialise MED3000 throughout the
EEA, the United Kingdom and Switzerland.
Futura is pleased to confirm that Cooper is on track to launch
Eroxon (TM) in the first half of 2023, as previously guided, and
has already commenced pre-launch activities and expects the first
product supplies to be available in the coming months.
James Barder, Chief Executive Officer of Futura Medical said:
"As part of our close strategic partnership with Cooper, we are
pleased to note that as planned, Eroxon will soon be made available
to men suffering from ED, especially those with mild and moderate
ED, to improve their erectile performance in a fast, safe,
effective and accessible way. We look forward to updating the
market further in due course."
MED3000 is the first pan-European topical treatment for ED
available without the need of a doctor's prescription and available
over the counter ("OTC"). Subject to US Food and Drug
Administration ("FDA") granting Marketing Authorisation, MED3000
has the potential to become the first major ED treatment available
OTC throughout the USA.
Futura has established a network of licensing and distribution
partners with strength in brand building, pharmaceutical
credibility and regional infrastructure and marketing expertise for
long-term distribution of MED3000 Eroxon(TM) across the globe.
To date, Futura has signed commercial agreements in key markets
including; European Economic Area (EEA), the United Kingdom, the
Gulf Co-operation Council (GCC) region, Switzerland and South
Korea, and now has a strong and expanding distribution platform in
place for regions outside the key US market. As announced in
December Futura's corporate advisors formally commenced the search
for a US commercial partner and continue to be engaged in a number
of ongoing discussions.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction ("ED") through a
unique evaporative mode of action. Futura has previously conducted
a Phase 3 study using MED3000 in ED, referred to as "FM57". This
was a 1,000 patient, dose-ranging, multi-centre, randomised, double
blind, placebo-controlled, home use, parallel group study
delivering highly statistically significant results compared to
pre-treatment baseline, using measures IIEF-EF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over
60% of patients experiencing a clinically meaningful improvement in
their ED.
MED3000 is CE marked in Europe and CA marked in the UK as a
clinically proven topical treatment for adult men with erectile
dysfunction under the brand Eroxon(TM) with a key claim of "Helps
you get an erection within 10 minutes".
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
About Cooper Consumer Health Group (CCH)
Cooper Consumer Health Group (CCH) is the largest independent
selfcare organization in Europe that is active in the OTC consumer
healthcare market with the development, manufacturing, selling and
marketing of selfcare products (e.g., medicines, medical devices,
cosmetics, biocides and food supplements) under its own or licensed
brands.
The ambition of our group is to offer selfcare solutions to
everyone based on a European brands portfolio. CCH has proven its
capacity to integrate new activities and aggregate talents by
capitalising on the strengths and the structure of its group.
www.cooper-healthcare.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASEFFMIEDSEFF
(END) Dow Jones Newswires
January 26, 2023 02:00 ET (07:00 GMT)
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023
